Skeletal conditions such as developmental dysplasia of the hip (DDH), osteoporosis, and osteoarthritis affect millions ...
FDA approves Ono Pharmaceutical's Romvimza for TGCT, meaning it will compete with Daiichi Sankyo's Turalio. Drug shows better safety profile and twice-weekly dosing vs twice-daily Turalio.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback